Hsbc Holdings PLC Buys Shares of 41,297 Roivant Sciences Ltd. $ROIV

Hsbc Holdings PLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, Holdings Channel.com reports. The firm acquired 41,297 shares of the company’s stock, valued at approximately $896,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. raised its position in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares during the period. Allworth Financial LP grew its position in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the period. Kestra Advisory Services LLC acquired a new position in shares of Roivant Sciences in the 4th quarter valued at approximately $47,000. CIBC Private Wealth Group LLC increased its stake in Roivant Sciences by 7,614.3% during the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares in the last quarter. Finally, Clearstead Advisors LLC increased its stake in Roivant Sciences by 141.6% during the 4th quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock worth $63,000 after purchasing an additional 1,704 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on ROIV shares. Citigroup boosted their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. Guggenheim boosted their target price on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, TD Cowen raised their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.59.

Roivant Sciences Stock Up 1.2%

Roivant Sciences stock opened at $34.91 on Wednesday. The company’s 50-day moving average price is $31.33 and its two-hundred day moving average price is $27.95. The stock has a market cap of $25.11 billion, a P/E ratio of -58.18 and a beta of 1.11. Roivant Sciences Ltd. has a twelve month low of $10.90 and a twelve month high of $37.00.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The firm had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. During the same quarter last year, the business earned ($0.29) EPS. Equities analysts anticipate that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. The trade was a 11.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.38, for a total transaction of $610,245.00. Following the transaction, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This represents a 51.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,345,687 shares of company stock worth $77,017,443 in the last ninety days. 10.80% of the stock is owned by company insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.